Mutations in the epidermal growth factor receptor (EGFR) gene are established therapeutic targets within lung cancer treatment paradigms, with an overall somatic mutation rate of 30.6% in the Chinese NSCLC population [4, 5]. Here, EGFR is linked to lung carcinoma.